Recro Pharma Provides Clinical Strategy Update Following

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Recro Pharma Provides Clinical Strategy Update Following Interim Analysis for Phase IIb Clinical Trial of Dex-IN

Analgesia in a subset of patients (50%), suggests therapeutic potential for Dex-IN in Post Op Day 1

Trial not expected to reach statistical significance as single agent on Post Op Day 0

Company to launch new study of Dex-IN 50 mcg in Post Op Day 1 bunionectomy model in Q4 2014; top line results estimated mid-year 2015

MALVERN, Pa., Sept. 4, 2014 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq: REPH ), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery, announced a clinical strategy update following findings from a prespecified interim analysis conducted on the initial half of patients who completed enrollment in the Company's REC-13-012 trial. The trial is a double blind, placebo-controlled study of intranasal dexmedetomidine, Dex-IN, in the treatment of acute post-operative pain following bunionectomy surgery on Post Op Day 0. While analgesia and a reduction in opioid use were observed in a subset of patients, the study is not expected to reach statistical significance in its current design. As a result, the Company plans to close this study and launch a revised study starting in Q4 2014. The Company will evaluate Dex-IN 50 mcg versus placebo in management of post-op pain starting Post Op Day 1 after bunionectomy surgery. Note that there were no serious adverse events observed in the REC-13-012 trial.

"There remains a significant unmet medical need for opioid-sparing analgesics, a need which we continue to believe may be addressed with Dex-IN," said Gerri Henwood, Recro Pharma's President and Chief Executive Officer. "Observations from an interim analysis of the REC-13-012 trial, however, suggest that the current study design will not allow us to reach statistical significance for single agent Dex-IN in a bunionectomy pain model starting on Post Op Day 0. That said, analgesia and corresponding reduction in opioid use, observed in a subset of patients, suggest that Dex-IN may serve as an effective pain management tool in a Post Op Day 1 bunionectomy study model. Based on what we know about the trajectory of pain, together with these observations, which confirm our earlier trial results and demonstrate efficacy for the first time in acute post-op pain, we believe that a study of 50 mcg Dex-IN in a Post Op Day 1 setting is the best path forward."

The interim analysis was based on the primary endpoint, SPID48 (summed pain intensity difference over 48 hours). This preplanned interim analysis was designed to allow for possible sample size adjustment. The results of the interim analysis (n=68, approximately 22 patients per group) revealed that the efficacy of Dex-IN as a stand alone drug was not sufficient to manage severe pain in bunionectomy on post operative day zero, Post Op Day 0. As a result, increased sample size is unlikely to be an effective modification of the trial.

In the interim analysis, the Company observed in patients with baseline pain intensity scores of ≤ 6 (N=34) that pain was more effectively managed on Post Op Day 0, as seen in the separation of scores between Dex-IN 50 mcg and Placebo (Table 1). In addition, based on an understanding of the trajectory of pain, it is recognized that pain on Post Op Day 0 is generally escalating, while pain on Post Op Day 1, or the day after surgery, is generally stable or declining. Based on the input from the Company's advisors, the results of the interim analysis and subset analyses, the information suggests that a post-operative pain management study in patients who initiate study treatment on Post Op Day 1 would be more effective than the current study design. The following table sets forth SPID48 scores from the interim analysis.

Table 1: SPID48
(In 34 patients with baseline pain intensity ≤6 and who completed 48 hour pain assessments)
     
Dex-IN 50 mcg Dex-IN 35 mcg Placebo
(n=12) (n=9) (n=13)
Mean (SD)    
48.67 (76.938) -9.67 (70.273) -10.60 (90.997)
Effect size (1)    
0.701 0.012 --
     
(1) Effect size quantifies the magnitude of the difference between two treatment groups (e.g., Dex-IN 50 mcg and placebo). An effect size of greater than 0.5 is typically considered good.

In addition, in this same population, opiate consumption (IV morphine and oral oxycodone) was reduced by approximately 50% versus placebo (Table 2). The following table sets forth the Rescue Medication used by patients in this population.

Table 2: Amount of Rescue Medication Used (morphine equivalence) (2)
(in 34 patients with baseline pain intensity ≤6 and who completed 48 hour pain assessments)
 Mean consumption – Mean (SD)
Dex-IN 50 mcg Dex-IN 35 mcg Placebo
(n=12) (n=9) (n=13)
   
5.83 (6.793) 10.67 (9.487) 11.85 (7.186)
 
(2) This trend was consistent for observation of morphine use (mg) and oxycodone use (mg).

Based on these observations, the input of Recro Pharma's advisors in post-operative pain, and results observed in earlier Dex pain studies, the Company believes that an effective clinical strategy going forward is to study Dex-IN 50 mcg versus placebo in the management of post-operative pain starting on Post Op Day 1 after bunionectomy surgery. The Company expects such a study would enroll between 150 and 200 subjects, and is targeting initiation in Q4 2014, with top line results estimated to be available mid-year 2015.  

About Recro Pharma, Inc.

Recro Pharma is a clinical stage specialty pharmaceutical company developing non-opioid, non-addictive therapeutics for the treatment of pain, initially for acute pain following surgery. Recro Pharma's lead product candidate, Dex-IN, is a proprietary intranasal formulation of dexmedetomidine and has completed a placebo controlled, proof of concept Phase Ib trial demonstrating effective pain relief. As Recro Pharma's product candidates are not in the opioid class of drugs, the Company believes its candidates would avoid many of the side effects associated with commonly prescribed opioid therapeutics, such as addiction, constipation and respiratory distress while maintaining analgesic effect. If approved, Dex-IN would be the first and only approved acute pain drug in its class of drugs.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect Recro Pharma's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Recro Pharma or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information available to Recro Pharma as of the date of this press release and are subject to a number of risks, uncertainties, and other factors that could cause Recro Pharma's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. Recro Pharma assumes no obligation to update any such forward-looking statements. Factors that could cause Recro Pharma's actual results to materially differ from those expressed in the forward-looking statements set forth in this press release include, without limitation: the results and timing of clinical trials of Dex-IN and any future clinical and preclinical studies; the ability to obtain and maintain regulatory approval of product candidates, and the labeling under any such approval; regulatory developments in the United States and foreign countries; the company's ability to raise future financing for continued development; the performance of third-party suppliers and manufacturers; the company's ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection; the successful commercialization of the company's product candidates; and the successful implementation of the company's strategy. In addition, the forward-looking statements in this press release should be considered together with the risks and uncertainties that may affect Recro Pharma's business and future results included in Recro Pharma's filings with the Securities and Exchange Commission at www.sec.gov .

Recro Pharma, Inc. Charles T. Garner Chief Financial Officer (484) 395-2425 Media and Investors: Argot Partners Susan Kim (212) 600-1902

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 18

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 52

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
Keiki Smiles Boosts Pediatric Dental Care in Waipahu

Updated Category News Views 76

A Neighborhood Dentists' Big Move: Keiki Smiles Expands in Waipahu Well, if there's one thing the dentists of Waipahu know how to do, it's adapt and grow. Keiki Smiles of Leeward, a trusted name in pediatric dentistry, just set up shop at a fresh location. The move marks a new chapter for this community staple, and honestly, it's miles more than just a longer lease and a...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 71

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Inventor Launches Handy Solution for Kids' Car Sickness

Updated Category News Views 5

A Fresh Take on an Age-Old Problem Just when you thought the universe had thrown all it could at beleaguered parents, here comes a nifty little accessory tackling those dreaded uphill battles with kids and car rides. Some bright spark from Middleburgh, New York, sick of scrubbing car seats and clothing every other road trip, came up with a clever little invention named...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 73

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Life Insurance: Evolving with Your Financial Journey

Updated Category News Views 56

Why Life Insurance Isn't Just a 'Set It and Forget It' Life insurance isn't some one-time deal you lock in and toss aside. Mike Newell, an insurance pro, highlights how life's shifts—whether in income, dependents, or debt—should drive tweaks to your coverage. As your life story unfolds, so too should the backbone of your financial security. Early Adulthood: Setting...

Continue Reading
AppLovin Faces Legal Heat: Investors on Edge Today

Updated Category News Views 43

AppLovin's Day of Reckoning: Investors Take Note Ever find yourself caught in a whirlwind of corporate promises that slide into disappointment? Well, buckle up, because that's exactly where AppLovin finds itself today. They've stirred up a storm with investors over some questionable hyperbole about their artificial intelligence tools and ad services. Missteps and Market...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 16

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading

Top 5 Most Recently Viewed Articles

PriceSmart Achieves Strong First Quarter Results and Expansion Plans

Updated Category News Views 229

PriceSmart Reports Impressive Growth in First Quarter of Fiscal 2026 PriceSmart, Inc. (NASDAQ: PSMT), with a presence across multiple regions, has announced substantial financial results for the first quarter of fiscal 2026, highlighting their ongoing growth and expansion strategies. The recent quarter ended on November 30, 2025, and the figures reflect a robust upward...

Continue Reading
Discover the New Belleza Community with Model Homes in California

Updated Category News Views 400

Exciting New Community in California Belleza at Lakeview is thrilled to announce the opening of their model homes, marking a significant step forward in the development of a brand new community in California. This community, designed with precision and style, invites potential homeowners to explore two stunning model homes, set to open soon for tours. Homebuyers are in...

Continue Reading
Bullish Nasdaq Signals Strong Potential for Long Investments

Updated Category News Views 89

Understanding Nasdaq's Recent Performance Recent market movements have highlighted a robust resurgence for bullish traders as they confidently regain control of their positions. The gains witnessed were particularly notable as the market showed resilience in defending critical support levels. Nasdaq's Bullish Technical Indicators As we explore the Nasdaq index, it becomes...

Continue Reading
Zero Homes Expands Services for Energy-Efficient Solutions

Updated Category News Views 123

Zero Homes Launches Comprehensive Services Across Colorado Zero Homes, a pioneering startup focused on digital solutions for home electrification, has announced its comprehensive statewide services tailored for every homeowner in Colorado. With its innovative approach, Zero Homes aims to guide residents in tapping into the newly established Colorado Home Energy Rebate...

Continue Reading
United Community Bank Foundation Commits $350,000 for Relief Aid

Updated Category News Views 107

United Community Bank Foundation's Commitment to Relief Efforts In the wake of the severe devastation caused by Hurricane Helene in the southern regions, the United Community Bank Foundation has stepped forward with a significant pledge. They are dedicating a remarkable amount of $350,000 to support local nonprofits that are actively engaged in the recovery and assistance...

Continue Reading